What guidance did BridgeBio Pharma's management provide for the next earnings period?

What is the market's earnings forecast for BridgeBio Pharma next quarter?

What is BridgeBio Pharma's gross profit margin?

Did BridgeBio Pharma beat or miss consensus estimates last quarter?

What is BridgeBio Pharma's latest dividend and current dividend yield?

What were the key takeaways from BridgeBio Pharma's earnings call?

What is the revenue and EPS growth rate for BridgeBio Pharma year over year?

What were the key takeaways from BridgeBio Pharma’s earnings call?

- **Revenue Growth**: Q4 2025 Attruby net product revenue $146M, full-year 2025 total revenue $502M (+126% YoY).
- **Pipeline Milestones**: 3 Phase III readouts (achondroplasia, LGMD2I, ADH1) with best-in-class data.
- **Cash Flow Outlook**: 2028 EBITDA >$600M from 4 assets; 2026 cash burn stabilization, 2027 decline.
- **Attruby Differentiation**: 2.1 cm/year growth in achondroplasia, 1-month clinical benefit onset, 50% price discount to competitors.
- **Infigratinib Market Share**: 65% peak share vs. 52% prior estimate.

**【CEO Summary Section】**
- Reported Q4 2025 net product revenue of $146 million for Attruby, driving total revenue to $154.2 million. Full-year 2025 revenue reached $502.1 million, up 126% YoY.
- Highlighted 3 successful Phase III readouts: infigratinib in achondroplasia (2.1 cm/year growth vs. placebo), BBP-418 in LGMD2I, and encaleret in ADH1. 
- Projected cash flow generation to begin in late 2027, with 2028 EBITDA of >$600 million from 4 post-Phase III assets.
- Attruby achieved >25% NBRx share in Q4, with 7,804 unique patient prescriptions as of Feb 2026.
- Infigratinib demonstrated best-in-class efficacy (2.1 cm/year growth, 0.41 SD height Z score improvement) and safety (no discontinuations, mild transient hyperphosphatemia only).

**【CFO Financial Commentary】**
- Q4 2025 GAAP net loss of $143.7 million (-$0.86 per share) vs. $105.3 million loss (-$0.63) in Q4 2024. Full-year 2025 net loss: $446 million (-$2.68 per share).
- Attruby gross margin improved to 65% in Q4, up from 55% in Q3. Full-year 2025 R&D expenses declined 55% YoY to $154.9 million.
- Ended 2025 with $587.5 million in cash, plus $632.5 million from January 2026 convertible notes issuance.
- Projected cash burn to stabilize in 2026, declining in 2027 as Attruby revenue scales.

**【Q&A Key Highlights】**
- **Attruby Growth Drivers**: Field team expertise, near-complete TTR stabilization, 1-month clinical benefit onset, and cardiorenal access differentiation. Q4 2025 new patient starts grew 35% QoQ.
- **IP Strategy**: U.S. tafamidis IP case set for April 2026 trial. Attruby priced at 50% discount to knockdown therapies, with clinical differentiation validated by 15% mortality risk reduction vs. tafamidis.
- **Pipeline Launch Readiness**: Global commercial teams built for 2026-2027 launches of BBP-418 (LGMD2I), encaleret (ADH1), and infigratinib (achondroplasia). Infigratinib expected 65% peak market share vs. 52% prior estimate.
- **Long-Term Capital Allocation**: Reinvest in R&D pipeline (Gondola collaborations), with optionality for buybacks/dividends if intrinsic value gap persists.

BridgeBio Pharma, Inc.(BBIO)-20260225-2025 Q4 Earnings call transcript

- **Phase III Triumphs**: BBP-418 (80% glycosylation improvement) and encaleret (76% calcium normalization) exceed expectations, solidifying first-in-class status.
- **Attruby Dominance**: $108.1M Q3 sales, targeting 30%+ market share with unique efficacy (43% CVH risk reduction) and lowest price point.
- **Pipeline Expansion**: Infigratinib Phase III readout in early 2026; chronic hypoparathyroidism and achondroplasia each project $2B+ opportunities.
- **Financial Strength**: $645.9M cash runway supporting commercial growth and late-stage trials.

**【CEO Summary Section】**
- Announced Phase III success for BBP-418 (LGMD2I) and encaleret (ADH1), with BBP-418 achieving 80% glycosylation improvement and encaleret normalizing calcium/PTH in 76% of patients.
- Attruby net product sales reached $108.1M, driven by 5,259 unique patient prescriptions and 1,355 unique HCPs. Targeting 30-35% market share by volume in ATTR-CM.
- Highlighted Attruby's differentiation as the only near-complete stabilizer with fastest time to separation, supported by 43% CVH risk reduction in arrhythmic patients.
- Encouraged by Bayer's 50% NBRx share in Germany for Beyonttra, and expanding pipeline with infigratinib (achondroplasia) Phase III readout expected in early 2026.

**【CFO Financial Commentary】**
- Q3 2025 total revenue: $120.7M (Attruby: $108.1M, royalties: $4.3M, others: $8.3M), up $118M YoY.
- Operating expenses: $259.3M (SG&A: +$68.8M, R&D: slight decline), reflecting investment in commercialization and late-stage trials.
- Cash position: $645.9M, providing runway for pipeline expansion.

**【Q&A Key Highlights】**
- **Attruby Market Share**: CEO estimates ~20-25% naive patient share, with focus on new patient capture (30%+ peak target). Switching dynamics limited due to combo therapy adoption.
- **Competitive Dynamics**: Attruby's lower price (~$100K vs. ~$200K for AMVUTTRA) and efficacy (43% CVH risk reduction) position it as long-term leader. Buy-and-bill incentives minimal in high-volume practices.
- **Pipeline Potential**: Encaleret for chronic hypoparathyroidism (~12,000 U.S. patients) and infigratinib for achondroplasia/hypochondroplasia ($2B+ TAM each) seen as key growth drivers. Infigratinib Phase III data expected early 2026.
- **Real-World Evidence**: ACT-EARLY trial to assess presymptomatic ATTR-CM intervention; JACC paper shows Attruby's impact on cardiac function优于Tafamidis.


BridgeBio Pharma, Inc. (BBIO) Q3 2025 Earnings Call Transcript

- **Attruby Dominance**: 100% Q2 revenue growth ($71.5M) with 3,751 patients; 30%+ weekly script acceleration vs. peers.
- **Clinical Breakthroughs**: 59% risk reduction in variant patients, 43% arrhythmia benefit; serum TTR mortality correlation validated.
- **Pipeline Milestones**: ADH1 Phase III readout Q4 2025; LGMD2I interim data Q4; hypochondroplasia program shows best-in-class efficacy.
- **Financial Strength**: $756M cash; 67% opex growth driven by commercial and R&D investments.

**【CEO Summary Section】**
- Attruby achieved 100% revenue growth in Q2 2025, with $71.5 million in U.S. net sales and 3,751 unique patient prescriptions. Weekly script growth exceeded 30%, driven by treatment-naive patients.
- Attruby demonstrated superior efficacy in variant (V122I) and arrhythmic subpopulations, with 59% and 43% risk reductions in mortality, respectively. Serum TTR levels correlate with 5% mortality risk reduction per mg/dL increase.
- Upcoming Phase III readouts for ADH1, LGMD2I, and achondroplasia in late 2025 and early 2026, with potential billion-dollar opportunities.

**【CFO Financial Commentary】**
- Total Q2 2025 revenue: $110.6 million (Attruby: $71.5M, royalties: $1.6M, others: $37.5M). 
- Operating expenses: $244.8 million (+67% YoY), driven by SG&A investments in Attruby and pipeline programs.
- Cash position: $756.9 million, supported by $300M European royalty monetization and strong Attruby sales.

**【Q&A Highlights】**
- Attruby captures ~20% of new-to-therapy patients, with 90% paying $0 out-of-pocket. Switching patients show 3.4 mg/dL serum TTR increase vs. tafamidis.
- ADH1 Phase III expected to show >50% response rate; LGMD2I interim data targets 5%+ glycosylation and 40% CK reduction.
- Encaleret for hypoparathyroidism normalizes calcium in 80% of patients within 5 days, with potential to reduce bone resorption.
- Inventory days of supply decreased due to just-in-time supply model, aligning with demand growth.

BridgeBio Pharma (BBIO)-5 Aug 25-2025 Q2 Earnings call transcript

- **Attruby Market Dominance**: $36.7M Q1 revenue, 30%-40% peak share target, lowest pricing in ATTR-CM space.
- **Clinical Superiority**: 42% CV mortality reduction at 30 months, 3-month efficacy separation vs. placebo.
- **Pipeline Momentum**: 3 Phase 3 readouts in H2 2025, Encaleret hypoparathyroidism POC success, LGMD2I accelerated approval path.
- **Financial Strength**: $540M cash, 9% NPV growth QoQ, cost-efficient launch with 31% gross margin.


**【CEO Summary Section】**
- Attruby generated $36.7 million in Q1 2025 net product revenue, driven by 2,072 unique patients and 756 prescribers. Early clinical data highlights a 42% relative risk reduction in cardiovascular mortality and hospitalization at 30 months, with separation from placebo at 3 months.
- Attruby is the only therapy with a free trial program and lifetime drug for trial participants, priced 10% lower than tafamidis and 50% lower than vutrisiran. The company aims for 30%-40% peak market share in the $15 billion ATTR-CM space.
- Pipeline progress includes fully enrolled Phase 3 trials for infigratinib (achondroplasia), BBP-418 (LGMD2I), and encaleret (hypoparathyroidism), with interim data expected in H2 2025.

**【CFO Financial Commentary】**
- Total Q1 2025 revenue: $116.6 million (Attruby: $36.7M; license/services: $79.9M). Operating expenses: $218.4 million, up 3.9% YoY, driven by commercial scale-up and pipeline advancement.
- R&D expenses decreased 23% YoY to $111.4 million due to oncology carve-out. SG&A rose 61% YoY to $106.4 million, reflecting Attruby launch costs.
- Cash balance: $540.6 million, with $105 million in pending milestones for Beyonttra ex-U.S. approvals.

**【Q&A Highlights】**
- Attruby conversion rates exceed industry benchmarks, with 48-hour patient access via specialty pharmacies.
- NPV increased 9% QoQ due to faster-than-expected uptake and pipeline enrollment acceleration.
- Encaleret shows 78% normalization of calcium levels in hypoparathyroidism POC, positioning for oral first-in-class status.
- LGMD2I interim data expected in H2 2025, with FDA alignment on glycosylated alpha-dystroglycan as surrogate endpoint for accelerated approval.


Actual			-0.78	-1.03	-0.98	-1.01	-1.18	-0.66	-1.06	-1.01	-1.35	-0.07	-0.93	-0.92	-0.92	-0.98	-1.08	-0.96	-0.2	-0.39	-0.86	-1.4	-0.88	-0.95	-0.95	-1
Forecast			-0.6888	-0.761	-0.8978	-0.8602	-0.75	-0.9716	-0.9146	-0.8819	-1.0863	-0.5567	-0.9681	-0.8381	-0.8225	-0.7988	-0.7934	-0.8689	-0.7368	-0.9981	-1.0033	-1.1202	-0.9179	-0.7934	-0.8941	-0.7134
Surprise	0.00%	0.00%	-13.24%	-35.35%	-9.16%	-17.41%	-57.33%	+32.07%	-15.90%	-14.53%	-24.28%	+87.43%	+3.94%	-9.77%	-11.85%	-22.68%	-36.12%	-10.48%	+72.86%	+60.93%	+14.28%	-24.98%	+4.13%	-19.74%	-6.25%	-40.17%

BBIO

BBIO fundamentals

BBIO Q4 2025 Earnings

Earnings Call

You can ask Aime

BBIO

BBIO fundamentals

BBIO Q4 2025 Earnings

Earnings Call

BBIO Earnings Call Summary for Q4/20254:30 PM on Feb 24, 2026

BBIO Earnings Call Summary for Q3/20254:30 PM on Oct 29, 2025

BBIO Earnings Call Summary for Q2/20254:30 PM on Aug 5, 2025

BBIO Earnings Call Summary for Q1/20254:30 PM on Apr 29, 2025

BBIO Earnings Call Summary for Q4/2024Invalid Date on Feb 20, 2025

You can ask Aime